Mycophenolate mofetil in high-risk patients with primary glomerulonephritis: Results of a 1-year prospective study

Nephron - Clinical Practice

Volumn 111, Issue 3, 2009, Pages

  Dimkovic, Nada ^a,i   Jovanovic, Dragan ^b   Kovacevic, Zoran ^b   Rabrenovic, Violeta ^b   Nesic, Vidosava ^c   Savin, Marina ^c   Mitic, Branka ^e   Ratkovic, Marina ^h   Curic, Slobodan ^f   Mitic, Igor ^f   Pljesa, Steva ^g   Perunicic Pekovic, Gordana ^g   Marinkovic, Jelena ^d   Popovic, Jovan ^a   Vujic, Danica ^a  

^a Zvezdara University   (Serbia)

^b Clinic for Nephrology   (Macedonia)

^c Institute for Urology and Nephrology

^d UNIVERSITY OF BELGRADE   (Serbia)

^e Institute for Nephrology

^f Clinical Center Novi Sad   (Yugoslavia)

^g Clinic for Internal Medicine   (Serbia)

^h Clinical Center of Montenegro   (Montenegro)

ⁱ University Hospital Zvezdara   (Serbia)

Author keywords

High risk patients; Mycophenolate mofetil; Primary glomerulonephritis

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CORTICOSTEROID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; FEMALE; GLOMERULONEPHRITIS; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 59249099144     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000199459     Document Type: Article

References (23)

1. Day CJ, Cockwell P, Lipkin GW, Savage COS, Howie AJ, Adu D: Mycophenolate mofetil in the treatment of resistant idiopathic nephritic syndrome. Nephrol Dial Transplant 2002;17:2011-2013.
2. Zhao M, Chen X, Chen Y, Liu Z, Lu F, Zhang Y, Wang H: Clinical observation of mycophenolate mofetil therapy in refractory primary nephritic syndrome. Nephrology 2003;8:105-109.
3. Mendizabal S, Zamora I, Berbel O, Sanahuja MJ, Fuentes J, Simon J: Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephritic syndrome. Pediatr Nephrol 2005;20:914-919.
4. Hogg RJ, Wyatt RJ, Scientific Planning Committee of the North American IgA Nephropathy Study: A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy. BMC Nephrol 2004;5:3. www.biomedcentral.com/ 1471-2369/5/3 (accessed December 2, 2008).
5. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YFC: Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-1849.
6. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishanan J, Preddie D, Crew J, Valeri A, Appel G: Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139-2145.
7. Tang S, Leung JK, Chan LYY, Lui YH, Tang CSO, Kan CH, HO YW, Lai KN: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68:802-812.
8. Montane B, Abitbol C, Chandar J, Strauss J, Zilleruelo G: Novel therapy of focal glomerulosclerosis with mycophenolate mofetil. Pediatr Nephrol 2003;18:771-777.
9. Gellermann J, Querfeld U: Frequently relapsing nephritic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004;19:101-104.
10. Tang S, Ho YW, Leung CY, Lai KN: Mycophenolate mofetil in the treatment of steroidresistant primary focal segmental glomerulosclerosis. J Nephrol 2005;18:429-432.
11. Polenakovic M, Grcevska L, Dzikova S: Mycophenolate mofetil in treatment of idiopathic stages II-IV membranous nephropathy. Nephrol Dial Transplant 2003;18:1233-1234.
12. Jones G, Juszczak M, Kindgdon E, Harber M, Sweny P, Burns A: Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004;19:3160-3164.
13. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-1114.
14. European Medicines Agency: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. London, EMEA, 2006. www.emea.europa.eu/ pdfs/human/ich/037795en.pdf (accessed December2, 2008).
15. Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003;23:324-332.
16. Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel GB: Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36:250-256.
17. du Buf-Verejiken P, Wetzels J: Mycophenolate mofetil (MMF) versus cyclophosphamide (CP) in patients with idiopathic membranousnephropathy (iMN) and renal insufficiency (abstract). Ann Meet Am Soc Nephrol, St Louis, 2004.
18. Bullo B, Zdrojewski Z, Rutkowski B: Mycophenolate mofetil (MMF) therapeutic approachin patients with chronic glomerulone phritis (GN). Kidney Int 2003;64:1138-1140.
19. Cattran DC, Appel GB, Hebert L, et al: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220-2226.
20. Matalon A, Valeri A, Appel GB: Treatment of focal segmental glomerulosclerosis. Sem Nephrol 2000;20:309-317.
21. Korbet SM: Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002;62:2301-2310.
22. Cattran DC, Wang MM, Appel GB, et al: Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62:405-411.
23. Segarra A, Amoedo ML, Martinez Garcia JM, Pons S, Praga M, Izquierdo Garcia E, et al: Efficacy and safety of 'rescue therapy'with mycophenolate mofetil in resistant primary glomerulonephritis: a multicenter study. Nephrol Dial Transplant 2007;22:1351-1360.